Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 17.06.2024 1 Ann Intern Med 4 BMJ 1 Infect Immun 1 J Gen Virol 3 J Infect Dis 1 J Virol 1 JAMA 1 MMWR Morb Mortal Wkly Rep 1 Nat Med 1 PLoS Comput Biol 1 PLoS Med 7 PLoS One 2 Proc Natl Acad Sci U S A 1 Science 17 Vaccine 2 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. DUTCHER EG, Epel ES, Mason AE, Hecht FM, et al
   COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study.
   Ann Intern Med. 2024 Jun 11. doi: 10.7326/M23-2956.
   PubMed         Abstract available
   
   

   
   BMJ

2. RAZAI MS, Berendes S, Nagraj S, Oakeshott P, et al
   As whooping cough rates rise, we urgently need to increase maternal vaccination rates.
   BMJ. 2024;385:q1289.
   PubMed        
   
   
3. LAL N
   Study on adverse effects following Covaxin stirs heated debate in India.
   BMJ. 2024;385:q1300.
   PubMed        
   
   
4. MURPHY F
   Whooping cough: Doctors urge Chinese authorities to review vaccine strategy as cases surge.
   BMJ. 2024;385:q1274.
   PubMed        
   
   
5. TORJESEN I
   Whooping cough: Doctors are urged to encourage vaccination as eight infants die in England amid case surge.
   BMJ. 2024;385:q1265.
   PubMed        
   
   

   
   Infect Immun

6. OSTAPCHUK YO, Lushova AV, Kan SA, Abdolla N, et al
   Long-term changes in the phenotype and cytokine production of monocytes in COVID-19 recovered and vaccinated individuals.
   Infect Immun. 2024 Jun 14:e0021624. doi: 10.1128/iai.00216.
   PubMed         Abstract available
   
   

   
   J Gen Virol

7. DEE K, Manali M, Bissett LA, Bone J, et al
   Smallpox vaccination campaigns resulted in age-associated population cross-immunity against monkeypox virus.
   J Gen Virol. 2024;105.
   PubMed         Abstract available
   
   

   
   J Infect Dis

8. LEROUX-ROELS I, Maes C, Mancini F, Jacobs B, et al
   Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial.
   J Infect Dis. 2024 Jun 10:jiae273. doi: 10.1093.
   PubMed         Abstract available
   
   
9. AMSTUTZ A, Chammartin F, Audige A, Eichenberger AL, et al
   Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
   J Infect Dis. 2024 Jun 7:jiae291. doi: 10.1093.
   PubMed         Abstract available
   
   
10. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
    Hybrid Immunity to SARS-CoV-2 During Pregnancy Provides More Durable Infant Antibody Responses Compared to Natural Infection Alone.
    J Infect Dis. 2024;229:1728-1739.
    PubMed         Abstract available
    
    

    
    J Virol

11. ZHU J, Wang Z, Li Y, Zhang Z, et al
    Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521.
    PubMed         Abstract available
    
    

    
    JAMA

12. DEAN N, Amin AB
    Test-Negative Study Designs for Evaluating Vaccine Effectiveness.
    JAMA. 2024 Jun 12. doi: 10.1001/jama.2024.5633.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

13. ADEGOKE OJ, Rachlin A, Porter AM, Katsande R, et al
    Migration from Epi Info to District Health Information Software 2 for Vaccine-Preventable Disease Surveillance - World Health Organization African Region, 2019-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:529-533.
    PubMed         Abstract available
    
    

    
    Nat Med

14. ZHONG Y, Kang AYH, Tay CJX, Li HE, et al
    Publisher Correction: Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
    Nat Med. 2024 Jun 10. doi: 10.1038/s41591-024-03107.
    PubMed        
    
    

    
    PLoS Comput Biol

15. WISTUBA-HAMPRECHT J, Reuter B, Fendel R, Hoffman SL, et al
    Machine learning prediction of malaria vaccine efficacy based on antibody profiles.
    PLoS Comput Biol. 2024;20:e1012131.
    PubMed         Abstract available
    
    

    
    PLoS Med

16. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    PubMed         Abstract available
    
    

    
    PLoS One

17. CHIEN LC, Marquez ER, Smith S, Tu T, et al
    Exploring the role of the social vulnerability index in understanding COVID-19 immunization rates.
    PLoS One. 2024;19:e0302934.
    PubMed         Abstract available
    
    
18. ASHCROFT R, Donnelly C, Sheffield P, Lam S, et al
    A qualitative examination of the experiences and perspectives of interprofessional primary health care teams in the distribution of the COVID-19 vaccination in Ontario, Canada.
    PLoS One. 2024;19:e0304616.
    PubMed         Abstract available
    
    
19. DALKY A, Quran TO, Abuhammad S, Al-Faraj HM, et al
    COVID-19 vaccine acceptance and associated factors among pregnant and lactating women attending maternity care clinics in refugee camps in Jordan.
    PLoS One. 2024;19:e0305314.
    PubMed         Abstract available
    
    
20. CHEN F, Nakanishi H, Sekizawa Y, Ochi S, et al
    Investigating the causal effects of COVID-19 vaccination on the adoption of protective behaviors in Japan: Insights from a fuzzy regression discontinuity design.
    PLoS One. 2024;19:e0305043.
    PubMed         Abstract available
    
    
21. BREWER SE, Bertin KB, Suresh K, LoudHawk-Hedgepeth C, et al
    Factors in COVID-19 vaccine uptake in five racial/ethnic Colorado communities: A report from the Colorado CEAL project.
    PLoS One. 2024;19:e0305160.
    PubMed         Abstract available
    
    
22. CHICOINE N, Schnipper N, Griffin J
    The role of hesitancy and infrastructure in the equity and efficiency of COVID-19 vaccine administration.
    PLoS One. 2024;19:e0304416.
    PubMed         Abstract available
    
    
23. CHEN LP, Singh-Verdeflor K, Kelly MM, Sklansky DJ, et al
    Disparities in COVID-19 vaccine intentions, testing and trusted sources by household language for children with medical complexity.
    PLoS One. 2024;19:e0305553.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. AFROZ S, Saul S, Dai J, Surman S, et al
    Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Proc Natl Acad Sci U S A. 2024;121:e2316376121.
    PubMed         Abstract available
    
    
25. WANG Y, Qu J, Xiong C, Chen B, et al
    Transdermal microarrayed electroporation for enhanced cancer immunotherapy based on DNA vaccination.
    Proc Natl Acad Sci U S A. 2024;121:e2322264121.
    PubMed         Abstract available
    
    

    
    Science

26. KHAN TU, Ahmad S
    Militancy facilitates polio spread in Pakistan.
    Science. 2024;384:967.
    PubMed        
    
    

    
    Vaccine

27. EMILIE HARTVIG RASMUSSEN C, Odgaard Vedel J, Moller Jensen A, Da Silva Borges I, et al
    Implementation of the vaccination program in Guinea-Bissau: Coverage and missed opportunities for BCG at birth.
    Vaccine. 2024 Jun 12:S0264-410X(24)00697-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
28. QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
    The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
    Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
29. SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
    Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
    Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
30. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
31. HOFFMAN E, Kahan T, Auerbach E, Brody H, et al
    Peer education as a strategy to promote vaccine acceptance: A randomized controlled trial within New York community healthcare practices.
    Vaccine. 2024 Jun 10:S0264-410X(24)00654-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
32. OTSUKI T, Akada S, Anami A, Kosaka K, et al
    Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
33. BRADY K, Lee A, Bassler J, Young Pierce J, et al
    Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
    Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
    Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
    Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
    Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. LI J, Gong L, Li J, Gong Z, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Vaccine. 2024;42:3751-3755.
    PubMed         Abstract available
    
    
38. BUCHHORN DE FREITAS S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, et al
    Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver nanoparticles protects mice from lethal infection by multidrug-resistant Acinetobacter baumannii.
    Vaccine. 2024;42:3802-3810.
    PubMed         Abstract available
    
    
39. AGARWAL S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, et al
    Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus.
    Vaccine. 2024;42:3899-3915.
    PubMed         Abstract available
    
    
40. DANELIAN G, Burton L, Bayley T, Sanchez-Marroquin A, et al
    The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Vaccine. 2024;42:3838-3850.
    PubMed         Abstract available
    
    
41. VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
    Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
    Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
42. DE POUVOURVILLE G, Guyot E, Farge G, Belhassen M, et al
    Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study.
    Vaccine. 2024 Jun 7:S0264-410X(24)00667-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
43. JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
    Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
    Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virology

44. BROGAARD L, Heegaard PMH, Larsen LE, Skovgaard K, et al
    Pulmonary MicroRNA expression after heterologous challenge with swine influenza A virus (H1N2) in immunized and non-immunized pigs.
    Virology. 2024;596:110117.
    PubMed         Abstract available
    
    
45. GE P, Ross TM
    COBRA HA and NA vaccination elicits long-live protective immune responses against pre-pandemic H2, H5, and H7 influenza virus subtypes.
    Virology. 2024;597:110119.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.